From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Efficacy parameters (total FMF cohort) | Baseline | 12 months | 24 months |
---|---|---|---|
Number of patients, N | 74 | 46 | 24 |
Number (%) of patients in disease remission (physician rating) | 22 (45) | 23 (72) | 12 (63) |
Patient assessment of current disease activity; 0–10, median (min; max) | 2.0 (0; 10) | 2.0 (0; 7) | 2.0 (0; 10) |
Patient assessment of current fatigue; 0–10, median (min; max) | 5.0 (0; 10) | 2.0 (0; 10) | 4.0 (0; 10) |
AIDAI score <9 ≙ inactive disease, N (%) | 12 (66.7) | 14 (58.3) | 8 (66.7) |
CRP / SAA, median (mg/dl) | 0.2 / 0.7 | 0.2 / 0.5 | 0.2 / 0.7 |
SAE (total FMF cohort) | Number of events | Incidence rate per 100 patient years | |
All types of SAE | 18 | 14.03 | |
SADR | 2 | 1.56 |